Comments
Drug firm Strides Pharma Science on Friday said its Singapore-based arm has received approval from the US health regulator for generic Oxybutynin Chloride tablets used to treat symptoms of overactive bladder and urinary incontinence.
Company’s step-down wholly owned subsidiary Strides Pharma Global Pte Ltd, Singapore, has received approval for Oxybutynin Chloride Tablets USP, 5 mg from the United States Food & Drug Administration (USFDA), Strides said in a filing to BSE.
The product is a generic version of Janssen Pharmaceuticals Inc’s Ditropan tablets in the same strength, it added.
The product will be manufactured at the company’s flagship facility at Bengaluru and will be marketed by Strides Pharma Inc in the US market, Strides said.
“According to IQVIA MAT October 2020 data, the US market for Oxybutynin Chloride tablets USP, 5 mg is approximately $29 million”, it added.
The company has 127 cumulative abbreviated new drug application (ANDA) filings with USFDA of which 94 ANDAs have been approved and 33 are pending approval, the filing said.
At 3.25 pm, shares of Strides Pharma Science were trading at Rs 776.25 on BSE, up 0.67 per cent from its previous close.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.